Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Immix Biopharma ( (IMMX) ).
On December 7, 2025, Immix Biopharma announced positive results from its Phase 2 trial of NXC-201 at the ASH 2025 Annual Meeting. The trial demonstrated a 75% complete response rate in patients with relapsed/refractory AL Amyloidosis, with potential future improvements to a 95% response rate. These results highlight NXC-201’s potential as a first-in-class therapy, with plans for a BLA submission in 2026, marking a significant step forward in addressing unmet medical needs in this field.
The most recent analyst rating on (IMMX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Immix Biopharma, Inc. is a global leader in the treatment of relapsed/refractory AL Amyloidosis, a severe disease where the immune system produces toxic light chains leading to organ failure. The company’s lead candidate is NXC-201, a BCMA-targeted CAR-T cell therapy designed to eliminate these toxic chains. NXC-201 has received Regenerative Medicine Advanced Therapy and Orphan Drug Designation from the FDA and EMA.
Average Trading Volume: 576,896
Technical Sentiment Signal: Buy
Current Market Cap: $186.7M
For detailed information about IMMX stock, go to TipRanks’ Stock Analysis page.